Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Could Orca-T Unlock New Path of Reduced Mortality, Prevent GVHD Posttransplant?

January 18th 2021

Steven Devine, MD, discusses the non-relapse mortality data with Orca-T and how this technologic approach is changing how providers approach patients with hematologic malignancies following transplant.

Dr. Rohs on the Role of Molecular Testing in Lung Cancer Management

January 18th 2021

Nicholas C. Rohs, MD, discusses the role of molecular testing in patients with lung cancer.

Dr. Subbiah on the Clinical Activity of Pralsetinib in RET+ Cholangiocarcinoma

January 16th 2021

Vivek Subbiah, MD, of The University of Texas MD Anderson Cancer Center, discusses the clinical activity of pralsetinib (Gavreto) in RET fusion-positive pancreatic cancer and cholangiocarcinoma.

Frontline Bemarituzumab/mFOLFOX6 Combo Improves Survival in Advanced FGFR2b+ Gastric/GEJ Cancer

January 16th 2021

Bemarituzumab combined with mFOLFOX6 demonstrated a 56% reduction in the risk of disease progression or death compared with placebo and mFOLFOX6 as a frontline treatment in select patients with FGFR2b-positive advanced gastric or gastroesophageal junction adenocarcinoma.

FDA Approves Crizotinib for Pediatric and Young Adult ALK+ Anaplastic Large Cell Lymphoma

January 14th 2021

January 14, 2021 - The FDA has approved crizotinib for the treatment of pediatric patients 1 year of age and older and young adults with ALK-positive relapsed or refractory, systemic anaplastic large cell lymphoma.

Novel Strategy Gains Traction Against HRAS-Mutant Cancers

January 14th 2021

Despite decades of research and drug development, however, the therapeutic utility of targeting RAS is limited to ruling out treatment with certain drugs in patients without RAS mutations.

Emerging Therapies May Offer Fresh Options for TP53-Mutated MDS

January 13th 2021

Two novel treatments options may shake up the landscape for treating patients with myelodysplasia syndrome.

Fleshing Out HER2-Directed Therapies in GI Malignancies

January 11th 2021

The field of HER2-positive gastrointestinal malignancies witnessed a surge of data in 2020 regarding investigational agents, such as the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki, that could play a pivotal role in transforming treatment selection in the coming years.

Larotrectinib Elicits Durable Responses, Extends Survival in TRK+ Sarcomas

January 11th 2021

January 11, 2021 - Larotrectinib was found to induce a high response rate with long durability and improve survival in patients with TRK-positive sarcomas, according to results from an analysis of 3 clinical trials.

Osimertinib/Bevacizumab Improves ORR, But Fails to Prolong PFS in EGFR T790M+ NSCLC

January 8th 2021

January 8, 2021 — The combination of osimertinib plus bevacizumab failed to result in a statistically significant improvement in progression-free survival versus osimertinib alone in patients with advanced lung adenocarcinoma that harbored an EGFR T790M mutation.

FDA Grants Fast Track Designation to Zenocutuzumab for Metastatic NRG1+ Solid Tumors

January 8th 2021

January 8, 2021 — The FDA has granted a fast track designation to zenocutuzumab for the treatment of patients with metastatic solid tumors that harbor NRG1 gene fusions and have progressed on standard-of-care treatment.

Approval for Amivantamab Sought in Europe for Metastatic EGFR Exon 20+ NSCLC

January 4th 2021

January 4th, 2021 - A marketing authorization application has been submitted to the European Medicines Agency for the approval of amivantamab as a treatment for patients with metastatic non–small cell lung cancer that harbors EGFR exon 20 insertion mutations who have experienced disease progression following platinum-based chemotherapy.

EU Approval Sought for Sotorasib in KRAS G12C–Mutated Advanced or Metastatic NSCLC

January 4th 2021

January 4, 2021 - A marketing authorization application has been submitted to the European Medicines Agency for the use of sotorasib in patients with KRAS G12C–mutated locally advanced or metastatic non–small cell lung cancer.

Manochakian Breaks Down Barriers to Genetic Testing in Lung Cancer

January 4th 2021

Rami Manochakian, MD, underscores the importance of looking for actionable alterations in lung cancer, barriers to genetic testing, and what is needed to overcome them.

Role for Somatic, Inherited Genetic Testing in Prostate Cancer Continues to Grow

January 3rd 2021

Leonard G. Gomella, MD, discusses the growing importance of genetic testing in prostate cancer.

Matching Novel Targets to Treatment Generates Excitement in TNBC

December 31st 2020

Neelima Vidula, MD, discusses the current and future utility of PARP inhibitors in triple-negative breast cancer, the promise of sacituzumab govitecan, and the need for germline genetic testing.

Pinpointing the Need for Genetic Testing in Oncology

December 31st 2020

Phuong L. Mai, MD, discusses the situations in which genetic testing should be considered and the importance of bridging awareness and access within oncology.

Learning to Tailor Targeted and Immune Therapy in Lung Cancer

December 14th 2020

Faculty of the MedStar Georgetown University Hospital-hosted Institutional Perspectives in Cancer webinar on lung cancer spotlight key advances made with targeted therapies in lung cancer, the ways in which immunotherapy has complicated treatment decisions, and more!

Expert Expands on Recent Advances With Actionable Alterations Spanning GI Cancers

December 7th 2020

Nathan Bahary, MD, PhD, discusses the importance of seeking targetable alterations in GI cancers, as well as recent advancements in the space.

Fruquintinib Enters Phase 3 Trial for Metastatic Colorectal Cancer

December 7th 2020

December 7, 2020 - The survival benefit of the novel agent fruquintinib will be tested during the phase 3 FRESCO-2 trial in patients with metastatic colorectal cancer who are either intolerant to or have received 3 prior lines of chemotherapy.